What is the 13F Pro Quality Score for ANGO?

13F Pro ranks ANGIODYNAMICS INC (ANGO) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View ANGO's current score at https://13fpro.ai/company/ANGO (free sign-up required for the full ranking).

Where does 13F Pro source ANGO data?

All ANGIODYNAMICS INC fundamentals and ownership data come directly from SEC EDGAR. ANGIODYNAMICS INC files with the SEC under CIK 1275187. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is ANGO in?

ANGIODYNAMICS INC (ANGO) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is ANGO research updated on 13F Pro?

ANGO's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

ANGIODYNAMICS INC(ANGO)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqsmall

Institutional-grade research for retail investors

SEC EDGAR: CIK 1275187 ANGO stock profile & AI dashboard →

13F Pro Quality Score

28.7/100

Rank #2,548 of 2,961 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

32.9/100

Profitability

20.6/100

Balance Sheet

14.5/100

Earnings Quality

48.9/100

Free Cash Flow

27.4/100

Institutional Flow

16.1/100

Revenue Scale

30.5/100

Dilution Risk

26.7/100

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why ANGO Scores 29/100

exact factor attribution · 2026-09-11

ANGO's composite is held back by profitability and capital efficiency. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Earnings quality

-0.1 pts

49th pct

Earnings growth

-0.6 pts

38th pct

Shareholder dilution

-1.2 pts

27th pct

Institutional flow

-1.7 pts

16th pct

Scale

-2.9 pts

31th pct

Free cash flow

-3.4 pts

27th pct

Revenue growth

-3.4 pts

33th pct

Capital efficiency

-3.5 pts

15th pct

Profitability

-4.4 pts

21th pct

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

ANGO Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for ANGIODYNAMICS INC (ANGO), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ANGO at 28.7/100 on a 32-signal composite quality model, placing it at rank #2,548 of 2,961 stocks — the bottom half of the AI-ranked universe. Areas of concern include balance sheet strength (14.5) and institutional flow (16.1), which score below median versus the broader universe. Shareholder dilution risk is elevated at 26.7/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), ANGIODYNAMICS INC reports quarterly revenue of $86.6M, net income of $-11.4M, an operating margin of -11.8%. Top institutional holders of ANGO by reported 13-F value include BlackRock, Point72 Asset Management, L.P., SYSTEMATIC FINANCIAL MANAGEMENT, based on the most recent SEC filings. ANGO trades on the Nasdaq exchange and files with the SEC under CIK 1275187. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ANGO daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for ANGIODYNAMICS INC directly from SEC EDGAR. ANGIODYNAMICS INC's 13F Pro composite quality score has ranged between 19 and 45 since 2021, currently 28.7 — an improving long-term trajectory across 68 quarterly and live scoring snapshots.

✦

Fun facts about ANGIODYNAMICS INC

Quirks, history, and lore behind ANGO — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. medical device company · small-cap · listed on Nasdaq · headquartered in upstate New York.
2
The Numbers
Annual revenue in the range of $300–400 million — not a giant, but a focused player serving hospitals and interventional specialists across the globe.
3
The History
Founded in the 1980s and built through decades of acquisitions, it carved out a niche in minimally invasive medical procedures targeting the vascular system.
4
The Secret
Its portfolio is laser-focused on venous and oncology applications — think devices that zap, drain, or clear things inside your blood vessels and tumors.
5
The Lore
It makes tools for ablation, thrombus management, and drainage — the unglamorous plumbing work that keeps interventional radiology suites humming every day.
6
The Giveaway
Its very name is a mashup of angio (blood vessels) and dynamics — and its ticker, ANGO, makes it pretty hard to hide.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q2 2026

$86.6M

Net Income

Q2 2026

$-11.4M

Free Cash Flow

Q2 2026

$17.0M

Operating Margin

Q2 2026

-11.8%

ROIC

Q2 2026

-23.9%

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+9.5% YoY

$320.2MFY 2026

FY23 $338.8MFY24 $303.9MFY25 $292.5MFY26 $320.2M

Net Income

-8.1% YoY

$-36.7MFY 2026

FY23 $-52.4MFY24 $-184.3MFY25 $-34.0MFY26 $-36.7M

Operating Income

+0.1% YoY

$-39.9MFY 2026

FY23 $-51.2MFY24 $-192.4MFY25 $-40.0MFY26 $-39.9M

EPS (Diluted)

-6.0% YoY

$-0.88FY 2026

FY23 $-1.33FY24 $-4.59FY25 $-0.83FY26 $-0.88

Total Assets

-4.6% YoY

$267.2MFY 2026

FY23 $532.6MFY24 $317.7MFY25 $280.1MFY26 $267.2M

Total Debt

—FY 2026

FY23 $49.8MFY24 $0.00FY25 —FY26 —

Op. Cash Flow

+130.5% YoY

$3.1MFY 2026

FY23 $78.0KFY24 $-28.2MFY25 $-10.1MFY26 $3.1M

Free Cash Flow

+103.5% YoY

$508.0KFY 2026

FY23 $-3.7MFY24 $-30.7MFY25 $-14.6MFY26 $508.0K

Metric	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Revenue	$320.2M +9.5%	$292.5M -3.8%	$303.9M -10.3%	$338.8M +7.1%	$316.2M +8.7%	$291.0M
Net Income	$-36.7M -8.1%	$-34.0M +81.6%	$-184.3M -251.5%	$-52.4M -97.5%	$-26.5M +15.9%	$-31.5M
Operating Income	$-39.9M +0.1%	$-40.0M +79.2%	$-192.4M -276.0%	$-51.2M -79.8%	$-28.5M +19.3%	$-35.3M
EPS (Diluted)	$-0.88 -6.0%	$-0.83 +81.9%	$-4.59 -245.1%	$-1.33 -95.6%	$-0.68 +17.1%	$-0.82
Total Assets	$267.2M -4.6%	$280.1M -11.8%	$317.7M -40.4%	$532.6M -3.6%	$552.8M -1.5%	$561.4M
Total Debt	—	—	$0.00 -100.0%	$49.8M +99.3%	$25.0M	—
Operating Cash Flow	$3.1M +130.5%	$-10.1M +64.0%	$-28.2M -36200.0%	$78.0K +101.1%	$-7.2M -129.9%	$24.1M
Free Cash Flow	$508.0K +103.5%	$-14.6M +52.4%	$-30.7M -721.5%	$-3.7M +67.5%	$-11.5M -160.8%	$18.9M

Get alerted when ANGO's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for ANGIODYNAMICS INC including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of ANGO

BlackRock, Inc.
$49.5M3,803,232 sh
Point72 Asset Management, L.P.
$39.8M3,062,517 sh
SYSTEMATIC FINANCIAL MANAGEMENT LP
$34.3M2,640,214 sh
ARMISTICE CAPITAL, LLC
$28.6M2,198,000 sh
ROYCE & ASSOCIATES LP
$25.6M1,969,835 sh
Broadfin Holdings LLC
$23.7M1,818,533 sh
VANGUARD CAPITAL MANAGEMENT LLC
$22.0M1,694,716 sh
WEBER CAPITAL MANAGEMENT LLC /ADV
$17.6M1,356,602 sh
Nuveen, LLC
$15.6M1,199,358 sh
GEODE CAPITAL MANAGEMENT, LLC
$13.3M1,020,658 sh

Fund	Value	Shares
BlackRock, Inc.	$49.5M	3,803,232
Point72 Asset Management, L.P.	$39.8M	3,062,517
SYSTEMATIC FINANCIAL MANAGEMENT LP	$34.3M	2,640,214
ARMISTICE CAPITAL, LLC	$28.6M	2,198,000
ROYCE & ASSOCIATES LP	$25.6M	1,969,835
Broadfin Holdings LLC	$23.7M	1,818,533
VANGUARD CAPITAL MANAGEMENT LLC	$22.0M	1,694,716
WEBER CAPITAL MANAGEMENT LLC /ADV	$17.6M	1,356,602
Nuveen, LLC	$15.6M	1,199,358
GEODE CAPITAL MANAGEMENT, LLC	$13.3M	1,020,658

Companies Similar to ANGO

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

TMCI

TREACE MEDICAL CONCEPTS, INC.

AI score

Very similar · 4 shared holders

ARMISTICE CAPITAL, LLC WEBER CAPITAL MANAGEMENT LLC /ADV JACOBS LEVY EQUITY MANAGEMENT, INC

IRIX

IRIDEX CORP

AI score

Similar quality profile · 1 shared holders

WEBER CAPITAL MANAGEMENT LLC /ADV

OSUR

ORASURE TECHNOLOGIES INC

AI score

Similar quality profile · 6 shared holders

SYSTEMATIC FINANCIAL MANAGEMENT LP KOTLER KEVIN First Eagle Investment Management, LLC

ARAY

ACCURAY INC

AI score

Similar quality profile · 3 shared holders

ARMISTICE CAPITAL, LLC WEBER CAPITAL MANAGEMENT LLC /ADV JACOBS LEVY EQUITY MANAGEMENT, INC

VNDA

Vanda Pharmaceuticals Inc.

AI score

Similar quality profile · 4 shared holders

JACOBS LEVY EQUITY MANAGEMENT, INC KENNEDY CAPITAL MANAGEMENT LLC KOTLER KEVIN

PTCT

PTC THERAPEUTICS, INC.

AI score

Similar quality profile · 9 shared holders

ARMISTICE CAPITAL, LLC SEGALL BRYANT & HAMILL, LLC Phocas Financial Corp.

INGN

Inogen Inc

AI score

Similar quality profile · 3 shared holders

ARMISTICE CAPITAL, LLC JACOBS LEVY EQUITY MANAGEMENT, INC MOORE CAPITAL MANAGEMENT, LP

IART

INTEGRA LIFESCIENCES HOLDINGS CORP

AI score

Similar quality profile · 4 shared holders

SYSTEMATIC FINANCIAL MANAGEMENT LP PARADIGM CAPITAL MANAGEMENT INC/NY KOTLER KEVIN

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put ANGO on your watchlist

Track score changes the day ANGIODYNAMICS INC files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is ANGO a good stock to buy?

13F Pro's AI-powered analysis of ANGIODYNAMICS INC (ANGO) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ANGO are available on the ANGO stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. ANGO is classified as a small company.

Which hedge funds own ANGO?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ANGO. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of ANGIODYNAMICS INC's investment landscape.